Renin-angiotensin gene polymorphisms and neurohormonal inhibition

Daniel F Pauly

doi:10.1016/j.hfc.2009.08.003

Renin-angiotensin gene polymorphisms and neurohormonal inhibition

Heart Fail Clin. 2010 Jan;6(1):25-6. doi: 10.1016/j.hfc.2009.08.003.

Author

Daniel F Pauly¹

Affiliation

¹ Division of Cardiovascular Medicine, Section of Heart Failure and Transplantation, University of Florida College of Medicine, Box 100277, Gainesville, FL 32610, USA. paulydf@medicine.ufl.edu

PMID: 19945057
DOI: 10.1016/j.hfc.2009.08.003

Abstract

Analyses of polymorphisms in the renin-angiotensin system may never completely predict responsiveness to pharmacotherapy that blocks angiotensin-converting enzyme or the angiotensin receptor type 1. However, the pharmacogenetic studies that have been conducted to date are intriguing, and they illustrate the potential benefit of designing larger genome-wide clinical studies. Such studies will continue to define the role of renin-angiotensin pharmacogenetics in patients with heart failure due to underlying cardiac dysfunction.

Publication types

Review

MeSH terms

Angiotensin II Type 1 Receptor Blockers / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Antihypertensive Agents / therapeutic use
Heart Failure / drug therapy*
Heart Failure / genetics
Humans
Mass Screening
Polymorphism, Genetic*
Receptors, Angiotensin / genetics
Receptors, Drug / drug effects
Receptors, Drug / genetics
Renin-Angiotensin System / drug effects
Renin-Angiotensin System / genetics*

Substances

Angiotensin II Type 1 Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Receptors, Angiotensin
Receptors, Drug